PAQR8

Summary

PAQR8 (progestin and adipoQ receptor family member 8, HGNC:15708) is a protein-coding gene on chromosome 6p12.2, encoding Membrane progestin receptor beta (Q8TEZ7). Plasma membrane progesterone (P4) receptor coupled to G proteins.

Predicted to enable nuclear steroid receptor activity and steroid binding activity. Predicted to be involved in response to steroid hormone. Located in Golgi apparatus and plasma membrane.

Source: NCBI Gene 85315 — RefSeq curated summary.

At a glance

• Gene–disease (curated): schizophrenia (No Known Disease Relationship, GenCC)
• GWAS associations: 3
• Clinical variants (ClinVar): 53 total
• MANE Select transcript: NM_133367

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:15708
Approved symbol	PAQR8
Name	progestin and adipoQ receptor family member 8
Location	6p12.2
Locus type	gene with protein product
Status	Approved
Aliases	LMPB1, MPRB
Ensembl gene	ENSG00000170915
Ensembl biotype	protein_coding
OMIM	607780
Entrez	85315

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 13 protein_coding

ENST00000360726, ENST00000442253, ENST00000512121, ENST00000867242, ENST00000867243, ENST00000867244, ENST00000867245, ENST00000867246, ENST00000867247, ENST00000867248, ENST00000867249, ENST00000867250, ENST00000959994

RefSeq mRNA: 1 — MANE Select: NM_133367 NM_133367

CCDS: CCDS4941

Canonical transcript exons

ENST00000442253 — 2 exons

Exon	Start	End
ENSE00001138018	52362151	52362249
ENSE00002051968	52403162	52407777

Expression profiles

Bgee: expression breadth ubiquitous, 235 present calls, max score 98.89.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.2290 / max 54.2742, expressed in 91 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
68227	15.4614	1656
68232	0.1139	38
68231	0.0930	33
68225	0.0221	6

Top tissues by expression

253 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
inferior vagus X ganglion	UBERON:0005363	98.89	gold quality
globus pallidus	UBERON:0001875	98.52	gold quality
medial globus pallidus	UBERON:0002477	98.51	gold quality
subthalamic nucleus	UBERON:0001906	98.33	gold quality
lateral globus pallidus	UBERON:0002476	98.07	gold quality
medulla oblongata	UBERON:0001896	97.91	gold quality
substantia nigra pars reticulata	UBERON:0001966	97.88	gold quality
spinal cord	UBERON:0002240	97.88	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	97.81	gold quality
dorsal plus ventral thalamus	UBERON:0001897	97.80	gold quality
ileal mucosa	UBERON:0000331	97.78	gold quality
ventral tegmental area	UBERON:0002691	97.59	gold quality
pons	UBERON:0000988	97.33	gold quality
lateral nuclear group of thalamus	UBERON:0002736	97.27	gold quality
superior vestibular nucleus	UBERON:0007227	97.17	gold quality
substantia nigra pars compacta	UBERON:0001965	97.02	gold quality
postcentral gyrus	UBERON:0002581	96.93	gold quality
parietal lobe	UBERON:0001872	96.86	gold quality
midbrain	UBERON:0001891	96.43	gold quality
substantia nigra	UBERON:0002038	96.28	gold quality
corpus callosum	UBERON:0002336	96.15	gold quality
entorhinal cortex	UBERON:0002728	95.99	gold quality
colonic mucosa	UBERON:0000317	95.61	gold quality
occipital lobe	UBERON:0002021	95.21	gold quality
mucosa of sigmoid colon	UBERON:0004993	95.07	gold quality
mucosa of transverse colon	UBERON:0004991	95.06	gold quality
temporal lobe	UBERON:0001871	94.98	gold quality
Ammon’s horn	UBERON:0001954	94.88	gold quality
putamen	UBERON:0001874	94.85	gold quality
superior frontal gyrus	UBERON:0002661	94.81	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	10.55
E-MTAB-2983	no	23.69

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

130 targeting PAQR8, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-4776-3P	100.00	68.73	1340
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-568	99.98	69.86	2084
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-96-5P	99.95	72.80	2140
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-4760-3P	99.93	70.50	2385
HSA-MIR-6753-3P	99.93	66.57	637
HSA-MIR-7107-3P	99.93	66.73	627
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-515-5P	99.92	69.82	2343
HSA-MIR-519E-5P	99.92	69.62	2358
HSA-MIR-12133	99.92	71.82	2006
HSA-MIR-1271-5P	99.91	71.99	1972
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-3529-3P	99.90	73.55	3045
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-506-3P	99.89	73.55	3057
HSA-MIR-4671-3P	99.88	72.46	1045
HSA-MIR-129-5P	99.88	70.26	3273
HSA-MIR-12119	99.87	68.35	1653
HSA-MIR-4779	99.86	66.50	1583
HSA-MIR-4307	99.82	70.45	3374
HSA-MIR-4760-5P	99.80	69.88	1619
HSA-MIR-204-5P	99.79	71.62	2439

Literature-anchored findings (GeneRIF, showing 3)

• LMPB1 is indeed an integral membrane protein that targets to lysosomal structures. (PMID:11676489)
• Heterologous expression of MPRB in yeast confirms its ability to function as a membrane progesterone receptor. (PMID:18603275)
• Data show abundant mPRalpha (PAQR7), mPRbeta (PAQR8), and mPRgamma (PAQR5), but not classical nuclear PR (A or B isoforms) mRNA expression and mPRalpha protein expression in a panel of commonly used ovarian cancer cell lines. (PMID:21761364)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	paqr8	ENSDARG00000088828
mus_musculus	Paqr8	ENSMUSG00000025931
rattus_norvegicus	Paqr8	ENSRNOG00000067120
drosophila_melanogaster	AdipoR	FBGN0038984
caenorhabditis_elegans		WBGENE00016610
caenorhabditis_elegans		WBGENE00019643

Paralogs (10): ADIPOR2 (ENSG00000006831), MMD (ENSG00000108960), MMD2 (ENSG00000136297), PAQR5 (ENSG00000137819), ADIPOR1 (ENSG00000159346), PAQR6 (ENSG00000160781), PAQR4 (ENSG00000162073), PAQR3 (ENSG00000163291), PAQR7 (ENSG00000182749), PAQR9 (ENSG00000188582)

Protein

Protein identifiers

Membrane progestin receptor beta — Q8TEZ7 (reviewed: Q8TEZ7)

Alternative names: Lysosomal membrane protein in brain 1, Membrane progesterone P4 receptor beta, Membrane progesterone receptor beta, Progesterone and adipoQ receptor family member 8, Progestin and adipoQ receptor family member 8, Progestin and adipoQ receptor family member VIII

All UniProt accessions (2): Q8TEZ7, D6RCM7

UniProt curated annotations — full annotation on UniProt →

Function. Plasma membrane progesterone (P4) receptor coupled to G proteins. Seems to act through a G(i) mediated pathway. May be involved in oocyte maturation. Also binds dehydroepiandrosterone (DHEA), pregnanolone, pregnenolone and allopregnanolone.

Subcellular location. Cell membrane.

Tissue specificity. Highly expressed in the hypothalamus. Also expressed in spinal cord, kidney and testis.

Miscellaneous. Non-classical progesterone receptors involved in extranuclear signaling are classified in 2 groups: the class II progestin and adipoQ receptor (PAQR) family (also called mPRs) (PAQR5, PAQR6, PAQR7, PAQR8 and PAQR9) and the b5-like heme/steroid-binding protein family (also called MAPRs) (PGRMC1, PGRMC2, NENF and CYB5D2).

Similarity. Belongs to the ADIPOR family.

RefSeq proteins (1): NP_588608* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR004254	AdipoR/HlyIII-related	Family

Pfam: PF03006

UniProt features (16 total): topological domain 8, transmembrane region 7, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8TEZ7-F1	93.25	0.90

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 130 (showing top): AGGAAGC_MIR5163P, RRAGTTGT_UNKNOWN, GOBP_CELLULAR_RESPONSE_TO_LIPID, GOBP_OOGENESIS, GOBP_HORMONE_MEDIATED_SIGNALING_PATHWAY, MODULE_205, chr6p12, GOBP_CELLULAR_RESPONSE_TO_HORMONE_STIMULUS, GOBP_CELLULAR_PROCESS_INVOLVED_IN_REPRODUCTION_IN_MULTICELLULAR_ORGANISM, GOBP_RESPONSE_TO_STEROID_HORMONE, GOBP_RESPONSE_TO_HORMONE, GOBP_RESPONSE_TO_LIPID, GOBP_CELLULAR_RESPONSE_TO_STEROID_HORMONE_STIMULUS, GOBP_INTRACELLULAR_RECEPTOR_SIGNALING_PATHWAY, GOBP_STEROID_HORMONE_RECEPTOR_SIGNALING_PATHWAY

GO Biological Process (4): oogenesis (GO:0048477), response to steroid hormone (GO:0048545), cell differentiation (GO:0030154), nuclear receptor-mediated steroid hormone signaling pathway (GO:0030518)

GO Molecular Function (4): nuclear steroid receptor activity (GO:0003707), steroid binding (GO:0005496), protein binding (GO:0005515), lipid binding (GO:0008289)

GO Cellular Component (3): Golgi apparatus (GO:0005794), plasma membrane (GO:0005886), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	2
germ cell development	1
female gamete generation	1
response to hormone	1
response to lipid	1
cellular developmental process	1
steroid hormone receptor signaling pathway	1
nuclear receptor-mediated signaling pathway	1
nuclear receptor activity	1
nuclear receptor-mediated steroid hormone signaling pathway	1
lipid binding	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Protein interactions and networks

STRING

458 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PAQR8	EFHC1	Q5JVL4	921
PAQR8	PGRMC1	O00264	853
PAQR8	PGRMC2	O15173	839
PAQR8	CTSD	P07339	684
PAQR8	PGR	P06401	611
PAQR8	SERBP1	Q8NC51	574
PAQR8	CYB5D2	Q8WUJ1	531
PAQR8	PAQR5	Q9NXK6	530
PAQR8	PAQR7	Q86WK9	496
PAQR8	MMD	Q15546	478
PAQR8	NENF	Q9UMX5	475
PAQR8	NPTXR	O95502	445
PAQR8	MMD2	Q8IY49	439
PAQR8	GPER1	Q99527	425
PAQR8	PIGW	Q7Z7B1	418

IntAct

10 interactions, top by confidence:

A	B	Type	Score
EHHADH	PAQR8	psi-mi:“MI:0915”(physical association)	0.560
MPP1	PAQR8	psi-mi:“MI:0915”(physical association)	0.560
LEPROTL1	PAQR8	psi-mi:“MI:0915”(physical association)	0.560
EHHADH	PAQR8	psi-mi:“MI:0915”(physical association)	0.000
MPP1	PAQR8	psi-mi:“MI:0915”(physical association)	0.000
PAQR8	LEPROTL1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (4): PAQR8 (Two-hybrid), PAQR8 (Two-hybrid), PAQR8 (Two-hybrid), PAQR8 (Affinity Capture-RNA)

ESM2 similar proteins: A2A559, A2V7M9, A7YWP2, A8WFS8, B7F9G7, B9F6Z0, O57328, O70421, P18537, Q08463, Q08464, Q09749, Q0VFE3, Q10LN5, Q10Q65, Q24760, Q5JMH0, Q5N808, Q5Z653, Q651J5, Q652J4, Q657S5, Q67VS5, Q69P80, Q6DC77, Q6ETK9, Q6K991, Q6L8F7, Q6L8F9, Q6TCG2, Q6ZVX9, Q753H5, Q801D8, Q801G2, Q80ZE5, Q84N34, Q865K9, Q86V24, Q8BQS5, Q8IWX5

Diamond homologs: B7F9G7, Q10PI5, Q6ETK9, Q7ZVH1, Q84N34, Q865K9, Q86V24, Q8BQS5, Q8TEZ7, Q91VH1, Q93ZH9, Q94177, Q96A54, Q9SVF3, Q9SZG0, Q9VCY8, Q9ZUH8, Q6DC77, Q6TCG2, Q6TCG5, Q6TCH4, Q6ZVX9, Q801D8, Q80ZE5, Q9DCU0, Q9NXK6, Q801G2, Q80ZE4, Q865K8, Q86WK9, Q8N4S7, Q9JJE4, Q753H5

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

53 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	46
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

593 predictions. Top by Δscore:

Variant	Effect	Δscore
6:52362248:CGGTG:C	donor_loss	0.9900
6:52362249:GGTGA:G	donor_loss	0.9900
6:52362250:G:A	donor_loss	0.9900
6:52362251:TGAGT:T	donor_loss	0.9900
6:52362246:GCCG:G	donor_gain	0.9800
6:52362250:G:GG	donor_gain	0.9800
6:52362252:GA:G	donor_loss	0.9800
6:52365397:C:T	donor_gain	0.9800
6:52365451:G:GG	donor_gain	0.9800
6:52401500:GT:G	donor_gain	0.9800
6:52403157:TGCA:T	acceptor_loss	0.9800
6:52403158:GCAG:G	acceptor_loss	0.9800
6:52403160:A:AC	acceptor_loss	0.9800
6:52403161:G:GA	acceptor_loss	0.9800
6:52403160:A:AG	acceptor_gain	0.9700
6:52403161:G:GG	acceptor_gain	0.9700
6:52403161:GGTT:G	acceptor_gain	0.9700
6:52403160:AG:A	acceptor_gain	0.9600
6:52403160:AGGTT:A	acceptor_gain	0.9600
6:52403161:GG:G	acceptor_gain	0.9600
6:52403161:GGTTG:G	acceptor_gain	0.9600
6:52362281:TC:T	donor_gain	0.9500
6:52362286:T:G	donor_gain	0.9500
6:52373627:G:GG	donor_gain	0.9500
6:52403161:GGT:G	acceptor_gain	0.9500
6:52404285:C:T	donor_gain	0.9500
6:52362165:G:GT	donor_gain	0.9400
6:52403157:T:TA	acceptor_gain	0.9400
6:52362245:TGCCG:T	donor_gain	0.9300
6:52362246:GCCGG:G	donor_gain	0.9300

AlphaMissense

2294 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:52403379:C:A	R56S	0.999
6:52403653:A:C	D147A	0.999
6:52403653:A:T	D147V	0.999
6:52403889:A:C	S226R	0.999
6:52403891:C:A	S226R	0.999
6:52403891:C:G	S226R	0.999
6:52403447:C:A	N78K	0.998
6:52403447:C:G	N78K	0.998
6:52403451:T:A	W80R	0.998
6:52403451:T:C	W80R	0.998
6:52403603:C:A	H130Q	0.998
6:52403603:C:G	H130Q	0.998
6:52403652:G:C	D147H	0.998
6:52403654:C:A	D147E	0.998
6:52403654:C:G	D147E	0.998
6:52403667:A:C	S152R	0.998
6:52403669:C:A	S152R	0.998
6:52403669:C:G	S152R	0.998
6:52403905:G:C	R231P	0.998
6:52403437:A:T	E75V	0.997
6:52403589:A:C	S126R	0.997
6:52403591:C:A	S126R	0.997
6:52403591:C:G	S126R	0.997
6:52403652:G:T	D147Y	0.997
6:52403653:A:G	D147G	0.997
6:52403661:G:C	G150R	0.997
6:52403662:G:A	G150D	0.997
6:52403682:G:C	G157R	0.997
6:52403775:T:A	W188R	0.997
6:52403775:T:C	W188R	0.997

dbSNP variants (sampled 300 via entrez): RS1000167290 (6:52392372 G>A), RS1000202266 (6:52399787 A>G), RS1000272617 (6:52390807 G>A,C), RS1000320235 (6:52372664 C>T), RS1000322751 (6:52384178 T>C), RS1000332359 (6:52396976 C>T), RS1000346639 (6:52404558 A>G), RS1000395675 (6:52386015 T>C), RS1000495980 (6:52365856 C>T), RS1000530918 (6:52406865 G>A,T), RS1000533417 (6:52377827 A>G), RS1000581961 (6:52390562 C>T), RS1000667949 (6:52384520 G>A), RS1000737666 (6:52374220 A>G), RS1000789658 (6:52381175 T>C)

Disease associations

OMIM: gene MIM:607780 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
schizophrenia	No Known Disease Relationship	Unknown

Mondo (1): schizophrenia (MONDO:0005090)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST003180_2	Atopic march	2.000000e-08
GCST004603_26	Platelet count	7.000000e-11
GCST90002402_699	Platelet count	8.000000e-11

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0007755	atopic march
EFO:0004309	platelet count

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

46 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, decreases expression, increases methylation	4
Valproic Acid	affects expression, decreases expression, increases expression	4
Tretinoin	decreases expression, increases expression	3
Cyclosporine	decreases expression	3
trichostatin A	affects expression, increases expression	2
sodium arsenite	decreases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Tobacco Smoke Pollution	decreases expression	2
aristolochic acid I	decreases expression	1
GSK-J4	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	affects expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
beta-lapachone	decreases expression	1
arsenite	affects methylation	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
cupric chloride	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
di-n-butylphosphoric acid	affects expression	1
monomethylarsonous acid	decreases expression	1
K 7174	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
clothianidin	decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
gardiquimod	increases expression, decreases reaction	1
Temozolomide	decreases expression	1
Zoledronic Acid	increases expression	1
Fulvestrant	decreases methylation	1
Gemcitabine	increases expression	1
Air Pollutants	decreases expression, increases abundance	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00000374	PHASE4	COMPLETED	Treatment for First-Episode Schizophrenia
NCT00001656	PHASE4	COMPLETED	Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
NCT00007774	PHASE4	COMPLETED	To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
NCT00014001	PHASE4	COMPLETED	CATIE- Schizophrenia Trial
NCT00018668	PHASE4	COMPLETED	Antipsychotic Response in Schizophrenia
NCT00034801	PHASE4	COMPLETED	Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
NCT00034905	PHASE4	COMPLETED	A Comparison of Seroquel vs. Risperidone in Schizophrenia
NCT00036088	PHASE4	COMPLETED	Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
NCT00044187	PHASE4	COMPLETED	The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
NCT00044655	PHASE4	COMPLETED	Switching Medication to Treat Schizophrenia
NCT00048828	PHASE4	COMPLETED	Treating Drug-Resistant Childhood Schizophrenia
NCT00053703	PHASE4	COMPLETED	Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)
NCT00056498	PHASE4	COMPLETED	Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
NCT00061802	PHASE4	COMPLETED	Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
NCT00080327	PHASE4	COMPLETED	Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
NCT00088049	PHASE4	COMPLETED	Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
NCT00090012	PHASE4	COMPLETED	Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00100776	PHASE4	COMPLETED	Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
NCT00103571	PHASE4	COMPLETED	Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00108368	PHASE4	COMPLETED	The Effects of Risperidone and Olanzapine on Thinking
NCT00114595	PHASE4	COMPLETED	Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
NCT00130923	PHASE4	COMPLETED	Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
NCT00137020	PHASE4	COMPLETED	Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
NCT00140166	PHASE4	COMPLETED	Treatment of Acute Schizophrenia With Vitamin Therapy
NCT00145847	PHASE4	COMPLETED	Naltrexone Treatment of Alcohol Abuse in Schizophrenia
NCT00148564	PHASE4	COMPLETED	Energy Homeostasis Under Treatment With Atypical Antipsychotics
NCT00156715	PHASE4	COMPLETED	Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
NCT00158223	PHASE4	COMPLETED	Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia
NCT00159081	PHASE4	COMPLETED	One Year Drug Treatment in First-Episode Schizophrenia
NCT00159120	PHASE4	COMPLETED	Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
NCT00159133	PHASE4	COMPLETED	Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
NCT00159757	PHASE4	TERMINATED	12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
NCT00167817	PHASE4	COMPLETED	Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study
NCT00169026	PHASE4	TERMINATED	Alcoholism and Schizophrenia: Effects of Clozapine
NCT00169039	PHASE4	TERMINATED	Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
NCT00169065	PHASE4	COMPLETED	Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
NCT00169091	PHASE4	TERMINATED	Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia
NCT00176423	PHASE4	COMPLETED	Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
NCT00176436	PHASE4	COMPLETED	Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
NCT00177008	PHASE4	COMPLETED	Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety